Skip to main content

Advertisement

SpringerLink
Log in

Polyglandular autoimmune syndromes

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

In recent years, scientific knowledge pertaining to the rare ORPHAN polyglandular autoimmune syndrome (registered code ORPHA 282196) has accumulated.

Objective

To offer current demographic, clinical, serological and immunogenic data on PAS.

Methods

Review of the pertinent and current literature.

Results

Polyglandular autoimmune syndromes (PAS) are multifactorial diseases with at least two coexisting autoimmune-mediated endocrinopathies. PAS show a great heterogeneity of syndromes and manifest sequentially with a large time interval between the occurrence of the first and second glandular autoimmune disease. PAS cluster with several non-endocrine autoimmune diseases. In most endocrinopathies of PAS, the autoimmune process causes an irreversible loss of function, while chronic autoimmune aggressions can simultaneously modify physiological processes in the affected tissue and lead to altered organ function. The rare juvenile PAS type I is inherited in a monogenetic manner, whereas several susceptibility gene polymorphisms have been reported for the more prevalent adult types. Relevant for a timely diagnosis at an early stage is the screening for polyglandular autoimmunity in patients with monoglandular autoimmune disease and/or first degree relatives of patients with PAS. The most prevalent adult PAS type is the combination of type 1 diabetes with autoimmune thyroid disease.

Conclusions

Early detection of specific autoantibodies and latent organ-specific dysfunction is advocated to alert physicians to take appropriate action in order to prevent full-blown PAS disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kahaly GJ (2009) Polyglandular autoimmune syndromes. Eur J Endocrinol Eur Fed Endocr Soc 161(1):11–20. doi:10.1530/eje-09-0044

    Article  CAS  Google Scholar 

  2. Eisenbarth GS, Gottlieb PA (2004) Autoimmune polyendocrine syndromes. N Engl J Med 350(20):2068–2079. doi:10.1056/NEJMra030158

    Article  CAS  PubMed  Google Scholar 

  3. Cutolo M (2014) Autoimmune polyendocrine syndromes. Autoimmun Rev 13(2):85–89. doi:10.1016/j.autrev.2013.07.006

    Article  CAS  PubMed  Google Scholar 

  4. Martinez Lopez MM, Gonzalez Casado I, Alvarez Doforno R, Delgado Cervino E, Gracia Bouthelier R (2006) AIRE gene mutation in polyglandular syndrome type 1. Anales de pediatria 64(6):583–587

    Article  PubMed  Google Scholar 

  5. Hansen MP, Kahaly GJ (2013) Autoimmune polyglandular syndromes. Deutsche medizinische Wochenschrift 138(7):319–326. doi:10.1055/s-0032-1327355 (quiz 327-318)

    Article  CAS  PubMed  Google Scholar 

  6. Forster G, Krummenauer F, Kuhn I, Beyer J, Kahaly G (1999) Polyglandular autoimmune syndrome type II: epidemiology and forms of manifestation. Dtsch Med Wochenschr 124(49):1476–1481. doi:10.1055/s-2008-1035684

    Article  CAS  PubMed  Google Scholar 

  7. Hansen MP, Matheis N, Kahaly GJ (2015) Type 1 diabetes and polyglandular autoimmune syndrome: a review. World J Diabetes 6(1):67–79. doi:10.4239/wjd.v6.i1.67

    Article  PubMed  PubMed Central  Google Scholar 

  8. Claude HGH (1908) Insuffisance pluriglandulaire endocrinienne. J Physiol Pathol Gen 10:469–480

    Google Scholar 

  9. Eisenbarth GS, Wilson PW, Ward F, Buckley C, Lebovita H (1979) The polyglandular failure syndrome: disease inheritance, HLA type, and immune function. Ann Intern Med 91(4):528–533

    Article  CAS  PubMed  Google Scholar 

  10. Muir A, She JX (1999) Advances in the genetics and immunology of autoimmune polyglandular syndrome II/III and their clinical applications. Ann Med Interne 150(4):301–312

    CAS  Google Scholar 

  11. Betterle C, Zanchetta R (2003) Update on autoimmune polyendocrine syndromes (APS). Acta bio-medica: Atenei Parm 74(1):9–33

    Google Scholar 

  12. Arlt W, Allolio B (2003) Adrenal insufficiency. Lancet 361(9372):1881–1893. doi:10.1016/S0140-6736(03)13492-7

    Article  CAS  PubMed  Google Scholar 

  13. Husebye ES, Perheentupa J, Rautemaa R, Kampe O (2009) Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 265(5):514–529. doi:10.1111/j.1365-2796.2009.02090.x

    Article  CAS  PubMed  Google Scholar 

  14. Bensing S, Brandt L, Tabaroj F, Sjoberg O, Nilsson B, Ekbom A, Blomqvist P, Kampe O (2008) Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol 69(5):697–704. doi:10.1111/j.1365-2265.2008.03340.x

    Article  Google Scholar 

  15. Dittmar M, Kahaly GJ (2003) Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 88(7):2983–2992. doi:10.1210/jc.2002-021845

    Article  CAS  PubMed  Google Scholar 

  16. Quinkler M (2012) Addison’s disease. Medizinische Klinik, Intensivmedizin und Notfallmedizin 107(6):454–459. doi:10.1007/s00063-012-0112-3

    Article  CAS  PubMed  Google Scholar 

  17. Horie I, Kawasaki E, Ando T, Kuwahara H, Abiru N, Usa T, Yamasaki H, Ejima E, Kawakami A (2012) Clinical and genetic characteristics of autoimmune polyglandular syndrome type 3 variant in the Japanese population. J Clin Endocrinol Metab 97(6):E1043–E1050. doi:10.1210/jc.2011-3109

    Article  CAS  PubMed  Google Scholar 

  18. Yoshioka K, Ohsawa A, Yoshida T, Yokoh S (1993) Insulin-dependent diabetes mellitus associated with Graves’ disease and idiopathic hypoparathyroidism. J Endocrinol Investig 16(8):643–646

    Article  CAS  Google Scholar 

  19. Lupi I, Raffaelli V, Di Cianni G, Caturegli P, Manetti L, Ciccarone AM, Bogazzi F, Mariotti S, Del Prato S, Martino E (2013) Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders. J Endocrinol Investig 36(2):127–131

    Article  CAS  Google Scholar 

  20. Kisand K, Peterson P (2015) Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol 35(5):463–478. doi:10.1007/s10875-015-0176-y

    Article  CAS  PubMed  Google Scholar 

  21. Myhre AG, Halonen M, Eskelin P, Ekwall O, Hedstrand H, Rorsman F, Kampe O, Husebye ES (2001) Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin Endocrinol 54(2):211–217

    Article  CAS  Google Scholar 

  22. Sato K, Nakajima K, Imamura H, Deguchi T, Horinouchi S, Yamazaki K, Yamada E, Kanaji Y, Takano K (2002) A Novel Missense Mutation of <I>AIRE</I> gene in a patient with autoimmune polyendocrinopathy, candidiasis and ectodermal dystrophy (APECED), accompanied with progressive muscular atrophy: case report and review of the literature in Japan. Endocr J 49(6):625–633. doi:10.1507/endocrj.49.625

    Article  CAS  PubMed  Google Scholar 

  23. Dominguez M, Crushell E, Ilmarinen T, McGovern E, Collins S, Chang B, Fleming P, Irvine AD, Brosnahan D, Ulmanen I, Murphy N, Costigan C (2006) Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in the Irish population. J Pediatr Endocrinol Metab 19(11):1343–1352

    Article  CAS  PubMed  Google Scholar 

  24. Betterle C, Dal Pra C, Mantero F, Zanchetta R (2002) Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 23(3):327–364. doi:10.1210/edrv.23.3.0466

    Article  CAS  PubMed  Google Scholar 

  25. Betterle C, Lazzarotto F, Presotto F (2004) Autoimmune polyglandular syndrome type 2: the tip of an iceberg? Clin Exp Immunol 137(2):225–233. doi:10.1111/j.1365-2249.2004.02561.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Fatma M, Mouna E, Raouf H, Hajer F, Hatem M, Mohammed A (2014) Autoimmune polyglandular syndrome type II: epidemiological, clinical and immunological data. J Endocrinol Metab 4(4):101–109

    CAS  Google Scholar 

  27. Waterfield M, Anderson MS (2010) Clues to immune tolerance: the monogenic autoimmune syndromes. Ann N Y Acad Sci 1214:138–155. doi:10.1111/j.1749-6632.2010.05818.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wolff AS, Erichsen MM, Meager A, Magitta NF, Myhre AG, Bollerslev J, Fougner KJ, Lima K, Knappskog PM, Husebye ES (2007) Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 92(2):595–603. doi:10.1210/jc.2006-1873

    Article  CAS  PubMed  Google Scholar 

  29. Chan AY, Anderson MS (2015) Central tolerance to self revealed by the autoimmune regulator. Ann N Y Acad Sci 1356(1):80–89. doi:10.1111/nyas.12960

    Article  PubMed  PubMed Central  Google Scholar 

  30. Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES, Kampe O, Rorsman F, Peltonen L, Ulmanen I, Partanen J (2002) AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab 87(6):2568–2574. doi:10.1210/jcem.87.6.8564

    Article  CAS  PubMed  Google Scholar 

  31. Meloni A, Willcox N, Meager A, Atzeni M, Wolff AS, Husebye ES, Furcas M, Rosatelli MC, Cao A, Congia M (2012) Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients. J Clin Endocrinol Metab 97(4):1114–1124. doi:10.1210/jc.2011-2461

    Article  CAS  PubMed  Google Scholar 

  32. Barkia Beradhi S, Flesch BK, Hansen MP, Matheis N, Kahaly GJ (2015) HLA class II differentiates between thyroid and polyglandular autoimmunity. Horm Metab Res 48(4):232–237. doi:10.1055/s-0035-1559622

    Article  PubMed  Google Scholar 

  33. Flesch BK, Matheis N, Alt T, Weinstock C, Bux J, Kahaly GJ (2014) HLA class II haplotypes differentiate between the adult autoimmune polyglandular syndrome types II and III. J Clin Endocrinol Metab 99(1):E177–E182. doi:10.1210/jc.2013-2852

    Article  CAS  PubMed  Google Scholar 

  34. Bellone M (2001) Autoimmune disease: pathogenesis. In: eLS. Wiley. doi:10.1038/npg.els.0004000

  35. Kang SY, Oh JH, Song SK, Lee JS, Choi JC, Kang JH (2015) Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. Neurol Sci: Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 36(7):1167–1171. doi:10.1007/s10072-015-2236-8

    Article  Google Scholar 

  36. Ortega SB, Noorbhai I, Poinsatte K, Kong X, Anderson A, Monson NL, Stowe AM (2015) Stroke induces a rapid adaptive autoimmune response to novel neuronal antigens. Discov Med 19(106):381–392

    PubMed  PubMed Central  Google Scholar 

  37. Ramos-Lopez E, Lange B, Kahles H, Willenberg HS, Meyer G, Penna-Martinez M, Reisch N, Hahner S, Seissler J, Badenhoop K (2008) Insulin gene polymorphisms in type 1 diabetes, Addison’s disease and the polyglandular autoimmune syndrome type II. BMC Med Genet 9:65. doi:10.1186/1471-2350-9-65

    Article  PubMed  PubMed Central  Google Scholar 

  38. Huang W, Connor E, Rosa TD, Muir A, Schatz D, Silverstein J, Crockett S, She JX, Maclaren NK (1996) Although DR3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplotype is implicated only in beta-cell autoimmunity. J Clin Endocrinol Metab 81(7):2559–2563. doi:10.1210/jcem.81.7.8675578

    CAS  PubMed  Google Scholar 

  39. Maclaren NK, Riley WJ (1986) Inherited susceptibility to autoimmune Addison’s disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type I autoimmune polyglandular syndrome. J Clin Endocrinol Metab 62(3):455–459. doi:10.1210/jcem-62-3-455

    Article  CAS  PubMed  Google Scholar 

  40. Robles DT, Fain PR, Gottlieb PA, Eisenbarth GS (2002) The genetics of autoimmune polyendocrine syndrome type II. Endocrinol Metab Clin North Am 31(2):353–368

    Article  PubMed  Google Scholar 

  41. Dittmar M, Kahaly GJ (2010) Genetics of the autoimmune polyglandular syndrome type 3 variant. Thyroid: Off J Am Thyroid Assoc 20(7):737–743. doi:10.1089/thy.2010.1639

    Article  CAS  Google Scholar 

  42. Brabant G, Manns MP, Vogel A, Strassburg CP (2002) Autoimmun polyglanduläre Syndrome: Aspekte zu Pathogenese, Prognose und Therapie. Dtsch Arztebl Int 99(21):1428

    Google Scholar 

  43. Zlotogora J, Shapiro MS (1992) Polyglandular autoimmune syndrome type I among Iranian Jews. J Med Genet 29(11):824–826

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J (1990) Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 322(26):1829–1836. doi:10.1056/NEJM199006283222601

    Article  CAS  PubMed  Google Scholar 

  45. Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest 39(10):1105–1114. doi:10.1007/s40618-016-0505-x

    Article  CAS  PubMed  Google Scholar 

  46. Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, Gaiti M, Spreafico E, Gallo D, Premoli P, Piantanida E, Tanda ML, Ferrario M, Vitti P, Chiovato L (2016) The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Investig 39(12):1445–1451. doi:10.1007/s40618-016-0516-7

    Article  CAS  Google Scholar 

  47. Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marino M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curro N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ, European Group on Graves O (2017) Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Investig 40(5):547–553. doi:10.1007/s40618-017-0608-z

    Article  CAS  Google Scholar 

  48. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C (2009) Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Medicine 67(11):376–387

    Google Scholar 

  49. Kobayashi I, Inukai T, Takahashi M, Ishii A, Ohshima K, Mori M, Shimomura Y, Kobayashi S, Hashimoto A, Sugiura M (1988) Anterior pituitary cell antibodies detected in Hashimoto’s thyroiditis and Graves’ disease. Endocrinologia japonica 35(5):705–708

    Article  CAS  PubMed  Google Scholar 

  50. Wallaschofski H, Meyer A, Tuschy U, Lohmann T (2003) HLA-DQA1*0301-associated susceptibility for autoimmune polyglandular syndrome type II and III. Hormone and metabolic research=Hormon- und Stoffwechselforschung=Hormones et metabolisme 35(2):120–124. doi:10.1055/s-2003-39059

    Article  CAS  PubMed  Google Scholar 

  51. Betterle C, Greggio NA, Volpato M (1998) Clinical review 93: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 83(4):1049–1055. doi:10.1210/jcem.83.4.4682

    Article  CAS  PubMed  Google Scholar 

  52. Betterle C, Volpato M, Greggio AN, Presotto F (1996) Type 2 polyglandular autoimmune disease (Schmidt’s syndrome). J Pediatr Endocrinol Metab 9(Suppl 1):113–123

    PubMed  Google Scholar 

  53. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachee-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougneres PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, Casanova JL (2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207(2):291–297. doi:10.1084/jem.20091983

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Strobel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, Meager A (2010) Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207(2):299–308. doi:10.1084/jem.20091669

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Diana T, Wuster C, Kanitz M, Kahaly GJ (2016) Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 39(10):1159–1165. doi:10.1007/s40618-016-0478-9

    Article  CAS  PubMed  Google Scholar 

  56. Cardenas-Roldan J, Rojas-Villarraga A, Anaya JM (2013) How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med 11:73. doi:10.1186/1741-7015-11-73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ward L, Paquette J, Seidman E, Huot C, Alvarez F, Crock P, Delvin E, Kampe O, Deal C (1999) Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 84(3):844–852. doi:10.1210/jcem.84.3.5580

    CAS  PubMed  Google Scholar 

  58. O’Gorman CS, Shulman R, Lara-Corrales I, Pope E, Marcon M, Grasemann H, Schneider R, Upton J, Sochett EB, Koltin D, Cohen E (2013) A child with autoimmune polyendocrinopathy candidiasis and ectodermal dysplasia treated with immunosuppression: a case report. J Med Case Rep 7:44. doi:10.1186/1752-1947-7-44

    Article  PubMed  PubMed Central  Google Scholar 

  59. Abinun M, Hodges S, Cheetham T, Ognjanovic M, Hopper N, Burt A, Wood K, Lilic D (2014) ESID-0264 immunomodulatory therapy for severe autoimmune polyendocrinopathy type-1 (APS-1). J Clin Immunol 34(Suppl 2):139–515

    Google Scholar 

  60. Michels AW, Eisenbarth GS (2009) Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding autoimmune polyendocrine syndrome type 2 (APS-2). J Intern Med 265(5):530–540. doi:10.1111/j.1365-2796.2009.02091.x

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Johannes Gutenberg University Medical Center, 55101, Mainz, Germany

    G. J. Kahaly & L. Frommer

Authors
  1. G. J. Kahaly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Frommer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. J. Kahaly.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

This review does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

No informed consent needed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahaly, G.J., Frommer, L. Polyglandular autoimmune syndromes. J Endocrinol Invest 41, 91–98 (2018). https://doi.org/10.1007/s40618-017-0740-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-017-0740-9

Keywords

Search

Navigation